February 2022 FDA Recall Drug by Teligent Pharma, Inc.
D-0716-2022 - Failed Impurities/Degradation Specifications

This Class II drug recall was voluntarily initiated by Teligent Pharma, Inc. on February 7, 2022 for the product Drug. The FDA reported the reason for recall as failed impurities/degradation specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0716-2022

Reason for Recall
Failed Impurities/Degradation Specifications: Lot not meeting specification for Unknown Max Related Compounds.
Initiated
02-07-2022
Reported
02-23-2022
Quantity
11040 tubes

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Teligent Pharma, Inc.
Nationwide in the USA.
Erythromycin Topical Gel USP, 2%, Net Wt 30 g tube, Rx only, Manufactured by: Teligent Pharma, Inc., Buena, NJ 08310, Distributed by: McKesson Corporation, dba Sky Packaging, 4971 Southridge Blvd., Suite 101, Memphis, TN 38141, NDC 63739-053-66.

Batch or Lot Expiration Information

Lot# Lot: 15724, Exp. 06/2022